Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure

Nature Medicine

Volumn 22, Issue 10, 2016, Pages 1094-1100

  Malherbe, Stephanus T ^a,b   Shenai, Shubhada ^c   Ronacher, Katharina ^a,b   Loxton, Andre G ^a,b   Dolganov, Gregory ^d   Kriel, Magdalena ^a,b   Van, Tran ^d   Chen, Ray Y ^e   Warwick, James ^b,f   Via, Laura E ^e,g   Song, Taeksun ^h   Lee, Myungsun ^h   Schoolnik, Gary ^d   Tromp, Gerard ^a,b   Alland, David ^c   Barry, Clifton E ^a,b,e,g   Winter, Jill ⁱ   Walzl, Gerhard ^a,b   Lucas, Lance ^a,b   Spuy, Gian Van Der ^a,b   Stanley, Kim ^a,b   Theart, Lani ^a,b   Smith, Bronwyn ^a,b   Burger, Nelita ^a,b   Beltran, Caroline G G ^a,b   Maasdorp, Elizna ^a,b   Ellmann, Annare ^b,f   Choi, Hongjo ^h   Joh, Joonsung ^j   Dodd, Lori E ^e   Allwood, Brian ^b   Kogelenberg, Coenie ^b   Vorster, Morné ^b   Griffith Richards, Stephanie ^b   more..

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f STELLENBOSCH UNIVERSITY   (South Africa)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h International Tuberculosis Research Center   (South Korea)

ⁱ Catalysis Foundation for Health   (United States)

^j National Medical Center   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ISONIAZID; MESSENGER RNA; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LUNG LAVAGE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; SPUTUM; TREATMENT OUTCOME; TREATMENT RESPONSE; BRONCHOALVEOLAR LAVAGE FLUID; DIAGNOSTIC IMAGING; GENETICS; LUNG; METABOLISM; MICROBIOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; SOUTH AFRICA; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RNA, MESSENGER; SOUTH AFRICA; SPUTUM; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84987660805     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4177     Document Type: Article

References (69)

1. Cox, H. S., Morrow, M. & Deutschmann, P. W. Long term efficacy of DOTS regimens for tuberculosis: systematic review. Br. Med. J. 336, 484-487 (2008).
2. World Health Organization. Global tuberculosis report 2015 (WHO Press, Geneva, 2015).
3. Gillespie, S. H. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577-1587 (2014).
4. Jindani, A. et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med. 371, 1599-1608 (2014).
5. Luzze, H. et al. Relapse more common than re-infection in recurrent tuberculosis 1-2 years post treatment in urban Uganda. Int. J. Tuberc. Lung Dis. 17, 361-367 (2013).
6. Merle, C. S. et al. A 4-month gatifloxacin-containing regimen for treating tuberculosis. N. Engl. J. Med. 371, 1588-1598 (2014).
7. Sonnenberg, P. et al. HIV-1 and recurrence, relapse and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358, 1687-1693 (2001).
8. Stop TB Partnership. The global plan to stop TB 2016-2020. http://www.stoptb. org/global/plan/plan2/# (2016).
9. Johnson, J. L. et al. Shortening treatment in adults with non-cavitary tuberculosis and 2-month culture conversion. Am. J. Respir. Crit. Care Med. 180, 558-563 (2009).
10. Warner, D. F. & Mizrahi, V. Shortening treatment for tuberculosis-to basics. N. Engl. J. Med. 371, 1642-1643 (2014).
11. Seon, H. J., Kim, Y. I., Lim, S. C., Kim, Y. H. & Kwon, Y. S. Clinical significance of residual lesions in chest computed tomography after anti-tuberculosis treatment. Int. J. Tuberc. Lung Dis. 18, 341-346 (2014).
12. Ralph, A. P. et al. A simple, valid numerical score for grading chest X-ray severity in adult smear-positive pulmonary tuberculosis. Thorax 65, 863-869 (2010).
13. Pasipanodya, J. G. et al. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health 10, 259 (2010).
14. Wejse, C. et al. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand. J. Infect. Dis. 40, 111-120 (2008).
15. Pasipanodya, J. G. et al. Pulmonary impairment after tuberculosis. Chest 131, 1817-1824 (2007).
16. Pasipanodya, J. G. et al. Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest 132, 1591-1598 (2007).
17. Hnizdo, E., Singh, T. & Churchyard, G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 55, 32-38 (2000).
18. Ramos, L. M. M., Sulmonett, N., Ferreira, C. S., Henriques, J. F. & de Miranda, S. S. Functional profile of patients with tuberculosis sequelae in a university hospital. J. Bras. Pneumol. 32, 43-47 (2006).
19. Nihues, S., de S. E. et al. Chronic symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients. Braz. J. Infect. Dis. 19, 492-497 (2015).
20. Baig, I. M., Saeed, W. & Khalil, K. F. Post-tuberculous chronic obstructive pulmonary disease. J. Coll. Physicians Surg. Pak. 20, 542-544 (2010).
21. Mitchison, D. A. Basic mechanisms of chemotherapy. Chest 76 (Suppl. 6), 771-781 (1979).
22. Hu, Y. et al. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J. Bacteriol. 182, 6358-6365 (2000).
23. Rustad, T. R. et al. Global analysis of mRNA stability in Mycobacterium tuberculosis. Nucleic Acids Res. 41, 509-517 (2013).
24. Ignatov, D. V. et al. Dormant nonculturable Mycobacterium tuberculosis retains stable low-abundant mRNA. BMC Genomics 16, 954 (2015).
25. Cheebsumon, P. et al. Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment. J. Nucl. Med. 52, 1550-1558 (2011).
26. Huang, W. et al. Standard uptake value and metabolic tumor volume of [18F]FDG PET-CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small-cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 38, 1628-1635 (2011).
27. Dibble, E. H. et al. [18F]FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J. Nucl. Med. 53, 709-715 (2012).
28. Lin, P. L. et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat. Med. 20, 75-79 (2014).
29. Via, L. E. et al. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using 2-[18F]fluoro-deoxy-d-glucose positron emission tomography and computed tomography. Antimicrob. Agents Chemother. 56, 4391-4402 (2012).
30. Lin, P. L. et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob. Agents Chemother. 57, 4237-4244 (2013).
31. Coleman, M. T. et al. Early changes by [18F]fluorodeoxyglucose positron emission tomography co-registered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun. 82, 2400-2404 (2014).
32. Davis, S. L. et al. Non-invasive pulmonary 2-[18F]fluoro-deoxy-d-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53, 4879-4884 (2009).
33. Martinez, V. et al. [18F]FDG PET-CT in tuberculosis: an early non-invasive marker of therapeutic response. Int. J. Tuberc. Lung Dis. 16, 1180-1185 (2012).
34. Dureja, S., Sen, I. B. & Acharya, S. Potential role of [18F]FDG PET-CT as an imaging biomarker for the non-invasive evaluation in uncomplicated skeletal tuberculosis: a prospective clinical observational study. Eur. Spine J. 23, 2449-2454 (2014).
35. Demura, Y. et al. Usefulness of [18F]fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur. J. Nucl. Med. Mol. Imaging 36, 632-639 (2009).
36. Chen, R. Y. et al. PET-CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci. Transl. Med. 6, 265ra166 (2014).
37. Stelzmueller, I. et al. [18F]FDG PET-CT in the initial assessment and for follow-up in patients with tuberculosis. Clin. Nucl. Med. 41, e187-e194 (2016).
38. Sathekge, M., Maes, A., Kgomo, M., Stoltz, A. & Van de Wiele, C. Use of [18F]FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J. Nucl. Med. 52, 880-885 (2011).
39. World Health Organization. Treatment of Tuberculosis Guidelines 4th edn. (WHO Press, Geneva, 2010).
40. Walter, N. D. et al. Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis during treatment of human tuberculosis. J. Infect. Dis. 212, 990-998 (2015).
41. Lew, J. M., Kapopoulou, A. & Jones, L. M. C. S. TubercuList-TB gene database. http://tuberculist. epfl. ch/quicksearch. php?gene+name=Rv2031c.
42. Yuan, Y., Crane, D. D. & Barry, C. E. III. Stationary-phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial?-crystallin homolog. J. Bacteriol. 178, 4484-4492 (1996).
43. Mittl, R. L. Jr. et al. Radiographic resolution of community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 149, 630-635 (1994).
44. Friedrich, S. O. et al. Assessment of the sensitivity and specificity of Xpert MTB-RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir. Med. 1, 462-470 (2013).
45. Lahtinen, S. J. et al. Degradation of 16S rRNA, and attributes of viability of viable but nonculturable probiotic bacteria. Lett. Appl. Microbiol. 46, 693-698 (2008).
46. Marx, F. M. et al. The temporal dynamics of relapse and re-infection tuberculosis after successful treatment: a retrospective cohort study. Clin. Infect. Dis. 58, 1676-1683 (2014).
47. Middelkoop, K., Bekker, L.-G., Shashkina, E., Kreiswirth, B. & Wood, R. Retreatment tuberculosis in a South African community: the role of re-infection, HIV and antiretroviral treatment. Int. J. Tuberc. Lung Dis. 16, 1510-1516 (2012).
48. Breen, R. A. M. et al. How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis? Int. J. Tuberc. Lung Dis. 12, 44-49 (2008).
49. Marais, B. et al. Tuberculosis case definition: time for critical reassessment? Int. J. Tuberc. Lung Dis. 12, 1217-1218, author reply 1218 (2008).
50. Dooley, K. E. et al. Risk factors for tuberculosis treatment failure, default or relapse, and outcomes of retreatment, in Morocco. BMC Public Health 11, 140 (2011).
51. Panjabi, R., Comstock, G. W. & Golub, J. E. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int. J. Tuberc. Lung Dis. 11, 828-837 (2007).
52. Hesseling, A. C. et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int. J. Tuberc. Lung Dis. 14, 560-570 (2010).
53. Warren, R. M. et al. Patients with active tuberculosis often have different strains in the same sputum specimen. Am. J. Respir. Crit. Care Med. 169, 610-614 (2004).
54. Kritzinger, F. E. et al. No decrease in annual risk of tuberculosis infection in an endemic area in Cape Town, South Africa. Trop. Med. Int. Health 14, 136-142 (2009).
55. Shanaube, K. et al. Annual risk of tuberculous infection, using different methods, in communities with a high prevalence of TB and HIV in Zambia and South Africa. PLoS One 4, e7749 (2009).
56. Chien, D., Lodge, M. & Wahl, R. Reproducibility of liver and mediastinal blood pool F-18 activity as normal reference tissues. J. Nucl. Med. 52, 536 (2011).
57. Kinahan, P. E. & Fletcher, J. W. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin. Ultrasound CT MR 31, 496-505 (2010).
58. Fogh, S. E. et al. Pathological correlation of PET-CT-based auto-contouring for radiation planning of lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 78, S202-S203 (2010).
59. Delbeke, D. et al. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 14 (Suppl. 2), 30-40 (2009).
60. Lowe, V. J., Hoffman, J. M., DeLong, D. M., Patz, E. F. & Coleman, R. E. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J. Nucl. Med. 35, 1771-1776 (1994).
61. Hatt, M. et al. Reproducibility of [18F]FDG and 3-deoxy-3-[18F]fluorothymidine PET tumor volume measurements. J. Nucl. Med. 51, 1368-1376 (2010).
62. Dann, E. J. et al. A functional dynamic scoring model to elucidate the significance of post-induction interim [18F]fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma. Haematologica 95, 1198-1206 (2010).
63. Higashi, K. et al. [18F]FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small-cell lung cancer: analysis of a multicenter study. J. Nucl. Med. 46, 267-273 (2005).
64. Barrington, S. F. et al. Concordance between four European centers of PET reporting criteria designed for use in multicenter trials in Hodgkin lymphoma. Eur. J. Nucl. Med. Mol. Imaging 37, 1824-1833 (2010).
65. Jacomelli, M. et al. Bronchoscopy for the diagnosis of pulmonary tuberculosis in patients with negative sputum-smear microscopy results. J. Bras. Pneumol. 38, 167-173 (2012).
66. Conde, M. B. et al. Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis: experience at an acquired immune deficiency syndrome reference center in Rio de Janeiro, Brazil. Am. J. Respir. Crit. Care Med. 162, 2238-2240 (2000).
67. George, P. M. et al. Post-bronchoscopy sputum: improving the diagnostic yield in smear-negative pulmonary TB. Respir. Med. 105, 1726-1731 (2011).
68. Galagan, J. E. et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature 499, 178-183 (2013).
69. Commandeur, S. et al. An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. J. Immunol. 190, 1659-1671 (2013).